About GA-binding protein subunit beta-2
GA-binding protein subunit beta-2 (GABPB2) is a protein
from Homo sapiens identified by UniProt accession
Q8TAK5, 448 residues long.
MolForge cross-references it against 0 known binders and
87 disease associations.
Target properties
| Protein name | GA-binding protein subunit beta-2 |
| UniProt accession | Q8TAK5 |
| Gene | GABPB2 |
| Organism | Homo sapiens |
| Length | 448 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (87)
Diseases linked to this target (Open Targets).
- body height · score 0.19
- body mass index · score 0.19
- alcohol consumption measurement · score 0.15
- age at first sexual intercourse measurement · score 0.12
- osteoporosis · score 0.10
- age at menarche · score 0.10
- appendicular lean mass · score 0.09
- skin cancer · score 0.09
- non-melanoma skin carcinoma · score 0.09
- waist circumference · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8TAK5-F1 | alphafold | PREDICTED | 62.83 | — |
Amino-acid sequence (448 residues)
MSLVDLGKRL LEAARKGQDD EVRTLMANGA PFTTDWLGTS PLHLAAQYGH YSTAEVLLRA GVSRDARTKV DRTPLHMAAA DGHAHIVELL VRNGADVNAK DMLKMTALHW ATERHHRDVV ELLIKYGADV HAFSKFDKSA FDIALEKNNA EILVILQEAM QNQVNVNPER ANPVTDPVSM AAPFIFTSGE VVNLASLISS TNTKTTSGDP HASTVQFSNS TTSVLATLAA LAEASVPLSN SHRATANTEE IIEGNSVDSS IQQVMGSGGQ RVITIVTDGV PLGNIQTSIP TGGIGQPFIV TVQDGQQVLT VPAGKVAEET VIKEEEEEKL PLTKKPRIGE KTNSVEESKE GNERELLQQQ LQEANRRAQE YRHQLLKKEQ EAEQYRLKLE AIARQQPNGV DFTMVEEVAE VDAVVVTEGE LEERETKVTG SAGTTEPHTR VSMATVSS
Explore GA-binding protein subunit beta-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets